Drug Trial Radar · NCT03841058
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Aug 14, 2019
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Hospital for Special Surgery, New YorkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective randomized, double-blinded, placebo-controlled, phase 2, 12-month pilot to study the efficacy of abaloparatide in postmenopausal women needing lumbar spinal fusion surgery. A total of 72 women with low bone mass who are scheduled to undergo spinal fusion surgery will be randomized 2:1 in a blinded fashion to receive either 80 mcg of abaloparatide subcutaneously (SC) every day or an identical-appearing placebo SC for 6 months. As well as a total of 24 men in an open-label design will be enrolled as an extension to this study. The total anticipated enrollment updated to 97. Outcomes include surgical outcomes at one year, pain, and fusion bone mass volume (FBMV) as a marker of bone union at 6 months and 1 year.
Conditions
- Spinal Fusion
Interventions
AbaloparatideDrug
80 mcg delivered SC by a pen
PlaceboDrug
A pen to deliver a SC dose of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in measure of fusion mass bridging from transverse process to transverse processTime frame: one year
- Difference in incidence of adverse surgical outcomesTime frame: one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital for Special Surgery
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.